CYP19A1 and breast cancer: In a phase I trial comprising 26 HR + advanced breast cancer patients, pembrolizumab in combination with an aromatase inhibitor, exemestane was well-tolerated with an overall response of ≥ 12 weeks in 42% of patients [188].